Compliance with Universal Precautions is unacceptably low, as reflected by the circumstances of MCE. Increased efforts to ensure education in Universal Precautions, easy accessibility of protective barriers, and improved design of the barriers are necessary to improve compliance and reduce the risk of MCE.

The efficacy and toxicity of trimethoprim-sulfamethoxazole (TMP-SMZ) as primary prophylaxis against Pneumocystis carinii pneumonia (PCP) for patients with human immunodeficiency virus (HIV) infection was assessed by comparing the effects of two dosages (480 or 960 mg once a day) of the drug. The multicenter trial involved 260 HIV-infected patients with CD4 cell counts < 0.2 x 10(9)/L and no history of PCP. Patients were randomly assigned to the treatment groups. After a median follow-up of 376 days (range, 1-1219), none of the patients developed PCP. Most adverse reactions that required discontinuation were seen within the first month of TMP-SMZ use and were seen more frequently and earlier in the 960-mg group (hazard ratio, 1.4; 95% confidence interval, 0.95-2.02; P = .007). For patients with HIV infection, 480 mg of TMP-SMZ is as efficacious as but less toxic than 960 mg of the drug for primary prophylaxis against PCP.

Compliance with Universal Precautions is unacceptably low, as reflected by the circumstances of MCE. Increased efforts to ensure education in Universal Precautions, easy accessibility of protective barriers, and improved design of the barriers are necessary to improve compliance and reduce the risk of MCE.

By means of serial lung function tests we examined the changes in lung function and possible pulmonary long-term sequelae in AIDS patients with a primary episode of Pneumocystis carinii pneumonia (PCP). A total of 19 patients had lung function tests performed prospectively from the time of PCP diagnosis, at 7 days, 14 days, 1, 2, 3, 4.5, 6 and 9 months after PCP. Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) were both reduced to a median of 61% of predicted at PCP diagnosis, and were normalized within 1 month and 1 week respectively. The median pulmonary diffusing capacity for carbon monoxide (DLCO) was severely reduced to 43% of predicted during the acute infection. Although DLCO improved significantly during the first 2 months, it remained reduced at a median DLCO of 64% of predicted 9 months after PCP. We conclude that despite a general improvement in lung function during the first 2 months following the PCP diagnosis, ther was a persistent reduction in DLCO up to 9 months following PCP. The pathological mechanisms causing this reduction remain to be established.

No abstract